Cardiovascular disease in people with type 2 diabetes places a significant financial burden on healthcare and the wider economy. Our results emphasize the financial consequences of cardiovascular disease prevention strategies (Diabetic Medicine)
Diabetes News
Category: Cardiovascular
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
This second part of this 2-part review summarizes the findings of recent clinical trials and their clinical implications and describes ongoing trials and future areas of research (Journal of the American College of Cardiology)
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
This first part of this 2-part review provides an overview of the current understanding of the mechanisms of the cardio-metabolic-renal benefits of SGLT2i. The second part summarizes the recent clinical trials of SGLT2i (Journal of the American College of Cardiology)
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
In SUSTAIN and PIONEER combined, glucagon‐like peptide‐1 analogue semaglutide showed consistent effects on MACE versus comparators across varying CV risk. No effect of semaglutide on MACE was observed in subjects with prior HF (Diabetes, Obesity and Metabolism)
Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
sodium-glucose co-transporter 2 inhibitors (SGLT2i) empagliflozin has the capacity to restore mitochondrial function, ameliorate electrical and structural remodelling and prevent AF (Cardiovascular Diabetology)
Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes
Our study suggests that metformin use at the time of first AMI is associated with increased risk of cardiovascular disease and death in patients with T2DM, while its use post-AMI might be beneficial (Cardiovascular Diabetology)
Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes
To date, all CVOTs have shown non-inferiority versus placebo (both added to standard of care) against a primary endpoint of 3- or 4-point major adverse cardiovascular event (MACE), confirming CV safety of these treatments. Additionally, some CVOTs have shown superiority to placebo against the same MACE endpoint, suggesting a cardioprotective action for these treatments. This is reflected in guideline updates, which primary care physicians should consider when personalizing treatments (Primary Care Diabetes)
Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
Approximately one-third of patients with T2DM in the UK have concomitant CVD (Diabetes Therapy)
Association of Diabetes Mellitus With Health Status Outcomes in Young Women and Men After Acute Myocardial Infarction: Results From the VIRGO Study
At baseline, young adults with diabetes mellitus had poorer health status than those without diabetes mellitus. After AMI, however, they experienced significant improvements and diabetes mellitus was not associated with worse angina, SAQ‐physical limitations, mental functioning, and quality of life, after adjustment for baseline covariates (Journal of the American Heart Association)
ESC, EASD released updated guidelines for diabetes, CVD treatment
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition (European Heart Journal)
Glucose-lowering drugs and heart failure: Implications of recent cardiovascular outcome trials in type 2 diabetes
These CVOTs data have led to guideline recommendations indicating appropriate therapy to T2DM patients with HF not at glycemic control target with metformin therapy (Diabetes Research and Clinical Practice)
Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis
Metformin reduces cardiovascular mortality, all-cause mortality and CV events in CAD patients. For MI patients and CAD patients without T2DM, metformin has no significant effect of reducing the incidence of CV events. Metformin has a better effect of reducing the incidence of CV events than sulfonylureas (Cardiovascular Diabetology)
Predictors of cardiomyopathy in patients with type-2 diabetes mellitus with and without cardiovascular complications: A cross-sectional study
In summary, BNP and calcium levels were significantly elevated while zinc was significantly reduced in T2DM patients with cardiovascular complication. Results from the study also shown positive correlation between BNP, calcium, Troponin-I levels and blood pressure. However, further longitudinal studies required to confirm these findings (Diabetes Research and Clinical Practice)
Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus
Compared with men developing T2DM, women with T2DM do not have a significantly higher relative increase in cardiovascular risk, but ongoing sex disparities in prescribing should prompt heightened efforts to improve the standard and equity of diabetes mellitus care in women and men (Circulation)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors (Lancet)
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes
In this post hoc analysis of SUSTAIN 6, once-weekly semaglutide vs placebo reduced the risk of MACE in all subjects included in the trial, regardless of gender, age, or baseline CV risk profile (Cardiovascular Diabetology)
Factors Affecting Cardiovascular Risk in Children, Adolescents, and Young Adults with Type 1 Diabetes
The frequency of cardiovascular risk factors is high in youth with T1D and associated with diabetes duration, obesity, and metabolic control (Journal of Diabetes Research)
Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation
There is an incremental risk of ischemic stroke and MI from non-diabetics to non-insulin diabetics with the highest risk in insulin users. Protective effect of anticoagulation is attenuated with insulin use (American Heart Journal)
Cardiac syncope recurrence in type 2 diabetes mellitus patients vs. normoglycemics patients: the CARVAS study
T2DM patients have alterations of the autonomic nervous system, as result of cardiac autonomic neuropathy. However, T2DM diagnosis and autonomic dysfunction assessed by HRV alterations predicted VVS recurrence (Diabetes Research and Clinical Practice)
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
The first interim analysis from EMPRISE showed that compared with sitagliptin, the initiation of empagliflozin was associated with a decreased risk of HHF among patients with T2D as treated in routine care, with and without a history of cardiovascular disease (Circulation)
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 13
- Next Page »
Glycosmedia is also available as an App: